Abstract:Weitao Yao, 1 Xinhui Du, 1 Jiaqiang Wang, 1 Xin Wang, 1 Peng Zhang, 1 Xiaohui Niu 2 1 Bone and Soft Department, The Affiliated Cancer Hospital of Zheng Zhou University, He Nan Cancer Hospital, Zheng Zhou City, 450000, People's Republic of China; 2 Department of Orthopedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Peking University, Beijing, 100035, People's Republic of China Correspondence: Weitao Yao, Bone and Soft Department, The Affiliated Cancer Hospital of Zheng Zhou University, He Nan Cancer Hospital, 127 Dong Ming Road, Zheng Zhou City, 450000, People's Republic of China, Email Xiaohui Niu, Department of Orthopedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Peking University, No. 31 Xin Jie Kou Dong Jie, Xi Cheng District, Beijing, 100035, People's Republic of China, Email Objective: To analyze the effectiveness of the long-term (> 12 months) administration of anlotinib as a monotherapy or combined therapy in patients with advanced sarcomas. Methods: A retrospective analysis was conducted of patients with advanced sarcomas with measurable target lesions since 2018. Twenty-two of the patients had taken anlotinib regularly for > 12 months. The patients' general information and the drug's clinical efficacy and toxicity data were collected and statistically analyzed using RECIST 1.1 to measure the target lesions and tumor PFS time as the main endpoints. We used a swimmer plot to observe the drug's efficacy and duration, and employed a waterfall plot to express the best treatment effect. Results: The study included 14 male and 8 female patients, ranging in age from 14 to 75 (mean: 44.82) years. The primary diseases included alveolar soft part sarcoma, synovial sarcoma, leiomyosarcoma, and others. The metastasis sites were the lungs in fifteen cases, lymph nodes in four cases, and multiple sites in three cases. Fourteen patients had previously undergone chemotherapy. The current therapy protocol was oral anlotinib alone for nine cases, combination chemotherapy for nine cases, and combination immunotherapy (anti-PD-1) for four cases. The highest clinical efficacy was complete remission (CR) in four (18.18%) cases, partial response (PR) in five (22.73%) cases, and stable disease in 13 (59.09%) cases, with an odds ratio of response of 40.91%. The mean PFS for the CR, PR, and stable disease groups was 16.50, 14.50, and 29.31 months, respectively (p < 0.05). The main adverse effects included hand-foot syndrome, hypertension, and leukopenia. Conclusion: Anlotinib monotherapy or combination therapy can be more effective and safer for certain advanced sarcomas, with more extended maintenance and acceptable side effects. Clinical efficacy at the CR and PR levels might predict the long-term PFS in certain advanced sarcomas. Keywords: anlotinib, advanced sarcoma, targeted therapy, immunotherapy, clinical efficacy Bone and soft tissue sarcomas (STS) are a group of malignant tumors derived from mesenchymal tissue and are characterized by high heterogeneity, complicated subtypes, high malignancy, and few available therapeutic methods. Moreover, most sarcomas are prone to metastasis through blood vessels to vital organs such as the lungs. 1 The treatment of sarcoma is mainly based on extensive surgical resection, supplemented by perioperative radiotherapy, chemotherapy, and other treatments. 2–5 For localized tumors, the 5-year survival rate can reach 70%–80%; however, advanced and metastatic sarcomas have a 5-year survival rate below 20%. 5 The prognosis for patients with sarcomas remains poor, with a median overall survival (OS) of slightly more than 1 year. Therefore, exploring new methods for treating advanced sarcoma is a hot topic and challenging research area. Angiogenesis plays an essential role in tumor growth and metastasis, and blocking this pathway is a strategy that has been successfully employed in clinically treating cancer. 6–8 Receptor tyrosine kinases are among the most promising therapeutic targets and can be used to modulate cell proliferation, growth, angiogenesis, and metastasis in a wide range of cancers. 8–12 Anlotinib (AL3818) is a novel oral receptor tyrosine kinase inhibitor (TKI) that targets vascular endothelial growth factor receptors 2 and 3, fibroblast growth factor receptors 1–4, platelet-derived growth factor receptors α and β, c‐Kit, and Ret, 13 thereby exerting inhibitory effects on tumor growth and angiogenesis. A Phase I study of anlotinib by Sun et al 14 demonstrated promising antitumor potential against STS. A multicenter, Phase II study by Chi et al (NCT01878448) 15 investigated single‐agent anlotinib in 166 patients -Abstract Truncated-

Evaluation of Thyroid-Stimulating Hormone-Increased, Hypertriglyceridemia and Proteinuria As Markers of Anlotinib Efficacy in Advanced Soft Tissue Sarcoma.

Evaluation of Hypertension and Hand-Foot Syndrome As Markers of Anlotinib Efficacy in Advanced Soft Tissue Sarcoma.

Efficacy and Safety of Anlotinib in Advanced Soft Tissue Sarcoma: Results from One of Multi-Centers in a Phase IIB Trial (ALTER0203).

Exploration of Associations Between Adverse Drug Reactions and Clinical Outcomes in Anlotinib Treatment Against Medullary Thyroid Carcinoma (MTC): A Subgroup Analysis Based on the ALTER01031 Trial.

Efficacy of Anlotinib in Advanced Soft Tissue Sarcoma by Prior Lines of Therapy, Age and Dose Modification

Anlotinib for Metastasis Soft Tissue Sarcoma: A Randomized, Double-Blind, Placebo-Controlled and Multi-Centered Clinical Trial.

Efficacy of Anlotinib in Advanced Soft Tissue Sarcoma by Age, Gender, and ECOG Performance Status.

The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era

Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma

Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)

P2.03a-001 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Anlotinib Treatment In Locally Advanced Or Metastatic Medullary Thyroid Carcinoma: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iib Trial.

Anlotinib Versus Placebo As Adjuvant Therapy for Completely Resected High-Grade Soft Tissue Sarcomas: Interim Results of a Phase 2, Double-Blinded, Randomized Controlled Trial.

1920P Anlotinib in Medullary Thyroid Carcinoma: A Subanalysis Based on ALTER01031 Study for Patients with High Prognostic Risk

Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: Subgroup Analysis of a Phase IIB Trial (ALTER0203)

Efficacy and Safety of Anlotinib Plus TQB2450 in Patients with Advanced Soft Tissue Sarcoma: A Multicenter, Single Armed, Phase 1b Trial.

Third-line Treatment: A Randomized, Double-Blind, Placebo-Controlled Phase III ALTER-0303 Study—efficacy and Safety of Anlotinib Treatment in Patients with Refractory Advanced NSCLC.

Long-Term Efficacy and Safety of Anlotinib as a Monotherapy and Combined Therapy for Advanced Sarcoma

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.

Effect of Anlotinib As a Third-Line or Further Treatment on Overall Survival of Patients with Advanced Non–Small Cell Lung Cancer

The Efficacy Of Anlotinib In Squamous Cell Carcinoma (Scc) Patients With Or Without Hypertension In Alter0303: Anlotinib As A Third-Line Therapy In Patients With Advanced Non-Small Cell Lung Cancer (Nsclc).